《美容院:特殊待遇》在线播放,曹查理电影全部免费观看,一起愁愁免费观看高清版视频

R-10015

NMR下載 COA and HPLC MSDS下載
names：
R-10015
CAS號：
2097938-51-5
MDL Number： No data available
MF(分子式)： C20H19ClN6O2 MW(分子量)： 410.86
EINECS:No data available Reaxys Number:No data available
Pubchem ID:129896912 Brand:BIOFOUNT

R-10015(2097938-51-5)是一種用于 HIV 感染的廣譜抗病毒化合物，R-10015是高效選擇性的 LIMK 抑制劑，R-10015通過結合 ATP 結合口袋阻斷 LIMK，抑制人 LIMK1 的 IC₅₀ 值為 38 nM。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000862-10mg	10mg	99%	￥ 5568.00	￥ 5568.00		2-3天	- +	￥ 0.00
YZM000862-5mg	5mg	99%	￥ 3412.00	￥ 3412.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	R-10015(2097938-51-5)
英文別名	R-10015,2097938-51-5
CAS號	2097938-51-5
Inchi	InChI=1S/C20H19ClN6O2/c1-29-20(28)12-2-3-14-15(8-12)26-17(25-14)11-4-6-27(7-5-11)19-16-13(21)9-22-18(16)23-10-24-19/h2-3,8-11H,4-7H2,1H3,(H,25,26)(H,22,23,24)
InchiKey	MGRJCGXCUUCOQG-UHFFFAOYSA-N
分子式 Formula	C20H19ClN6O2
分子量 Molecular Weight	410.86
溶解度Solubility	生物體外In Vitro:DMSO溶解度62.5 mg/mL(152.12 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble)
性狀	灰白色至粉紅色固體粉末
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

R-10015(2097938-51-5)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染

R-10015(2097938-51-5) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:R-10015(2097938-51-5),R-10015試劑,R-10015抑制劑,R-10015的作用,R-10015的合成,R-10015的純度,R-10015的生產,R-10015的使用,R-10015的外觀,R-10015的溶解度,R-10015的含量,R-10015的選擇,R-10015的MSDS

產品說明	R-10015(2097938-51-5)是一種用于 HIV 感染的廣譜抗病毒化合物，R-10015是高效選擇性的?LIMK?抑制劑
Introduction	R-10015 (2097938-51-5) is a broad-spectrum antiviral compound for HIV infection, R-10015 is a highly effective and selective LIMK inhibitor
Application1
Application2
Application3

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1
Abstract:A dynamic actin cytoskeleton is necessary for viral entry, intracellular migration, and virion release. For HIV-1 infection, during entry, the virus triggers early actin activity by hijacking chemokine coreceptor signaling, which activates a host dependency factor, cofilin, and its kinase, the LIM domain kinase (LIMK). Although knockdown of human LIM domain kinase 1 (LIMK1) with short hairpin RNA (shRNA) inhibits HIV infection, no specific small-molecule inhibitor of LIMK has been available. Here, we describe the design and discovery of novel classes of small-molecule inhibitors of LIMK for inhibiting HIV infection. We identified R10015 as a lead compound that blocks LIMK activity by binding to the ATP-binding pocket. R10015 specifically blocks viral DNA synthesis, nuclear migration, and virion release. In addition, R10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1), suggesting that LIMK inhibitors could be developed as a new class of broad-spectrum antiviral drugs.IMPORTANCE The actin cytoskeleton is a structure that gives the cell shape and the ability to migrate. Viruses frequently rely on actin dynamics for entry and intracellular migration. In cells, actin dynamics are regulated by kinases, such as the LIM domain kinase (LIMK), which regulates actin activity through phosphorylation of cofilin, an actin-depolymerizing factor. Recent studies have found that LIMK/cofilin are targeted by viruses such as HIV-1 for propelling viral intracellular migration. Although inhibiting LIMK1 expression blocks HIV-1 infection, no highly specific LIMK inhibitor is available. This study describes the design, medicinal synthesis, and discovery of small-molecule LIMK inhibitors for blocking HIV-1 and several other viruses and emphasizes the feasibility of developing LIMK inhibitors as broad-spectrum antiviral drugs.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開